Olumiant and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Olumiant (baricitinib).
High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Moderate Potential Hazard, Moderate plausibility
baricitinib - hyperlipemia
In controlled clinical trials in patients with rheumatoid arthritis, baricitinib treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Lipid parameters should be assessed at baseline and about 12 weeks after initiation of therapy in patients with rheumatoid arthritis or alopecia areata. Patients should be managed according to clinical guidelines for the management of hyperlipidemia.
References
- "Product Information. Olumiant (baricitinib)." Lilly, Eli and Company SUPPL-7 (2022):
Olumiant drug interactions
There are 455 drug interactions with Olumiant (baricitinib).
Olumiant disease interactions
There are 12 disease interactions with Olumiant (baricitinib) which include:
- infections
- tuberculosis
- cardiovascular risk
- malignancy
- thrombosis
- diabetes
- GI perforation
- hepatic impairment
- hyperlipemia
- laboratory abnormalities
- renal dysfunction
- viral hepatitis
More about Olumiant (baricitinib)
- Olumiant consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (11)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antirheumatics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.